Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISKPD-IFM2018-03 Isatuximab + Pomalidomide + Dexamethasone + Carfilzomib in Relapsed/Refractory Multiple Myeloma
2024-516670-29-00Phase 2Completed
- Sponsor
- CHU de Poitiers
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab, pomalidomide, dexamethasone and carfilzomib in multiple myeloma (MM), sponsored by CHU de Poitiers. Primary endpoint: Minimal residual disease (MRD) 10^-5 incidence rate. Started Aug 2024; status: completed.
02
Drugs
isatuximabpomalidomidedexamethasonecarfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-516670-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516670-29-00.